Ascelia Pharma – Presentation of Q1 2026 results
You can already sign up for the event and submit your questions. You don’t need to attend live to send in your questions for the presentation.
Ascelia Pharma is expected to release its Q1 2026 results on 12 May 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event.
The Q1 presentation arrives at a pivotal moment for Ascelia Pharma, with the FDA PDUFA decision date for Orviglance set for 3 July 2026 , and ongoing partnership discussions.
Therefore, in addition to the financial results, the presentation is expected to focus on the ongoing partnering process for Orviglance, which has been a central strategic priority. In connection with the FY 2025 results, CEO Magnus Corfitzen noted that multiple potential partners have demonstrated strong strategic interest, and that the now firmly established regulatory timeline has added momentum and clarity to these discussions.
Since the Q4 2025 report, it has reaffirmed the PDUFA date and the cash runway (Management has guided for a cash runway into Q4 2026, providing a buffer beyond the expected approval date) . The company also announced that Orviglance data has been accepted for oral presentation at the ESGAR Annual Meeting in Montpelier in June, one of the leading global forums for innovation in gastrointestinal and abdominal imaging , underlining the growing scientific interest in manganese-based contrast agents ahead of the FDA decision.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development – Orviglance® (Mangoral) and Oncoral. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 15.49, 14 April 2026.
